Diagnostic and prognostic biomarkers for Parkinsons disease

帕金森病的诊断和预后生物标志物

• 批准号: 8473525
• 负责人: RICHARD B DEWEY
• 金额: $ 64.53万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8473525
• 关键词: Age; Algorithms; Alzheimer' s Disease; Antibodies; Biological; Biological Markers; Blood; Clinical; Clinical Data; Clinical Trials Design; DNA analysis; Diagnosis; Diagnostic; Disease; Disease Progression; Gender; Grant; Libraries; Medical center; Medicine; Movement Disorders; National Institute of Neurological Disorders and Stroke; Parkinson Disease; Participant; Pathology; Patient Care; Patients; Peptoids; Plasma; Policies; Prevalence; Proteins; Public Health; Resources; Sampling; Scanning; Sensitivity and Specificity; Serum; Severity of illness; Specimen; Staging; Visit; base; biobank; data management; forest; medical schools; prognostic; programs; single photon emission computed tomography

DESCRIPTION (provided by applicant): Biomarkers that can detect PD pathology and that can detect disease progression will be most helpful for patient care and proper clinical trial design. As part of the NINDS Parkinson's Disease Biomarkers Program, we seek to collect biological specimens from PD patients and identify serum biomarkers for disease identification and tracking disease progression. PUBLIC HEALTH RELEVANCE: Because the prevalence of Parkinson's disease (PD) is on the rise, it is a public health necessity that the disease be diagnosed at its earliest stage in a relatively non-invasive manner. Biomarkers that can detect PD pathology, and that can detect disease progression would be most helpful for patient care and for proper clinical trial design. The current project seeks to identify serum biomarkers for PD and collect clinical data and new biological specimens from PD patients as part of the NINDS Parkinson's Disease Biomarkers Program.

描述（由申请人提供）：可以检测PD病理和疾病进展的生物标志物将对患者护理和适当的临床试验设计最有帮助。作为NINDS帕金森病生物标志物计划的一部分，我们寻求从PD患者中收集生物标本，并确定用于疾病识别和跟踪疾病进展的血清生物标志物。 公共卫生相关性：由于帕金森氏病（PD）的患病率正在上升，因此以相对非侵入性的方式在疾病的最早阶段进行诊断是公共卫生的必要性。可以检测PD病理学和可以检测疾病进展的生物标志物将对患者护理和适当的临床试验设计最有帮助。作为NINDS帕金森病生物标志物计划的一部分，当前项目旨在识别PD的血清生物标志物，并收集PD患者的临床数据和新生物样本。